Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
- 24 November 2008
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 64 (4), 1126-1136
- https://doi.org/10.1111/j.1541-0420.2008.01009.x
Abstract
Summary A Bayesian sequential dose-finding procedure based on bivariate (efficacy, toxicity) outcomes that accounts for patient covariates and dose-covariate interactions is presented. Historical data are used to obtain an informative prior on covariate main effects, with uninformative priors assumed for all dose effect parameters. Elicited limits on the probabilities of efficacy and toxicity for each of a representative set of covariate vectors are used to construct bounding functions that determine the acceptability of each dose for each patient. Elicited outcome probability pairs that are equally desirable for a reference patient are used to define two different posterior criteria, either of which may be used to select an optimal covariate-specific dose for each patient. Because the dose selection criteria are covariate specific, different patients may receive different doses at the same point in the trial, and the set of eligible patients may change adaptively during the trial. The method is illustrated by a dose-finding trial in acute leukemia, including a simulation study.Keywords
This publication has 22 references indexed in Scilit:
- Adaptive Dose Selection Using Efficacy-Toxicity Trade-Offs: Illustrations and Practical ConsiderationsJournal of Biopharmaceutical Statistics, 2006
- Individualized Patient Dosing in Phase I Clinical Trials: The Role of Escalation With Overdose Control in PNU-214936Journal of Clinical Oncology, 2004
- Bayesian Measures of Model Complexity and FitJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002
- Patient specific dosing in a cancer phase I clinical trialStatistics in Medicine, 2001
- TWO-SAMPLE CONTINUAL REASSESSMENT METHODJournal of Biopharmaceutical Statistics, 1999
- IMPROVED DESIGNS FOR DOSE ESCALATION STUDIES USING PHARMACOKINETIC MEASUREMENTSStatistics in Medicine, 1996
- Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and genderPharmacogenetics, 1996
- Model-Guided Determination of Maximum Tolerated Dose in Phase I Clinical Trials: Evidence for Increased PrecisionJNCI Journal of the National Cancer Institute, 1993